• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Groundbreaking HIV Vaccine Shows Success In Phase 1 Clinical Trial In Humans

December 2, 2022 by Deborah Bloomfield

Researchers report the positive results from a Phase 1 clinical trial focused on a vaccine against the Human Immunodeficiency Virus (HIV). The pathogen does not usually produce an immune response large enough to stop it, which has made it a dangerous and deadly virus. One of the goals in the creation of a vaccine is to find a formula that would indue the so-called broadly neutralizing antibodies (bnAb), an immune response that can step up to the challenge. And the trial shows that this vaccine can induce the bnAb precursors.

The results are fascinating. These bnAbs rarely develop during infection; in particular, bnAb-precursors B cells are uncommon in humans. But creating such an immune response would prime the body to fight infections from the globally diverse strains of HIV. And this approach could be used not just for HIV but for influenza, the hepatitis C virus, and betacoronaviruses.

Advertisement

In this Phase 1 trial, the participants received either two doses of placebo or two doses of the vaccine, either a low-dose version or a high-dose. These were administrated eight weeks apart. The vaccine had a favorable safety profile and it induced the right response in 35 out of the 36 recipients of the vaccine.  



The approach is known as germline targeting. There are a small number of B cells in the human body in their “naïve” or “germline” state. If they encounter a pathogen, these cells will weakly bind to it, and over the course of weeks, they will produce better and better antibodies that can fully attach themselves to the virus surface and neutralize it.

The vaccine aims to stimulate these B cells to produce bnAbs. Previous attempts might have not been successful because they did not stimulate enough B cells. 

Advertisement

While the results are very promising, it is not a straightforward step to a full vaccine against HIV. But the methods show an incredible level of control over the responses and could herald a new era of precision vaccine designs. And not just for HIV.

The development of such a vaccine, especially if distributed equitably across the world, would be revolutionary. Currently, 38.4 million people are estimated to be living with HIV, two-thirds of them in Africa. There is no cure for the infection but given the proper medication, people can live long and healthy lives. And if the viral load falls below the detection level, it is impossible for the virus to be passed on. This is defined by the slogan U=U, undetectable equals untransmittable.

And while vaccines are still a thing of the future, there is a drug called PrEP (pre-exposure prophylaxis) currently available, which effectively reduces the chance of infection by 99 percent. While great strides have been made in understanding and fighting this disease, access to life-saving drugs and to educational material about it remains incredibly unequal, with the most marginalized and at-risk communities receiving the least. Stigma, poverty, education, access to healthcare, racism, homophobia, and transphobia are the main reasons why individuals can’t get the help they need.

Advertisement

There has also been a distinct lack of public and government-sponsored campaigns aimed to inform and destigmatize the infection, and too often politicians and religious leaders have contributed to the spread of ignorance and misunderstanding about both HIV and AIDS.

We can’t all help find a vaccine or a cure for HIV infections, but fighting the stigma surrounding the virus and demanding our elected leaders provide equitable access to life-saving drugs is something we can all do.

The results were published in the journal Science. 

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Life insurers shift to pre-pandemic norms after COVID vaccine roll-outs
  2. Inspiration4 crew, meet outer space: SpaceX’s first all-civilian mission launches to orbit
  3. Democrats mobilize to extend government funding, avert shutdown
  4. We Can Make Oxygen On Mars So Reliably That It Will Sustain Human Exploration

Source Link: Groundbreaking HIV Vaccine Shows Success In Phase 1 Clinical Trial In Humans

Filed Under: News

Primary Sidebar

  • Project Hail Mary Trailer First Look: What Would Happen If The Sun Got Darker?
  • Newly Discovered Cell Structure Might Hold Key To Understanding Devastating Genetic Disorders
  • What Is Kakeya’s Needle Problem, And Why Do We Want To Solve It?
  • “I Wasn’t Prepared For The Sheer Number Of Them”: Cave Of Mummified Never-Before-Seen Eyeless Invertebrates Amazes Scientists
  • Asteroid Day At 10: How The World Is More Prepared Than Ever To Face Celestial Threats
  • What Happened When A New Zealand Man Fell Butt-First Onto A Powerful Air Hose
  • Ancient DNA Confirms Women’s Unexpected Status In One Of The Oldest Known Neolithic Settlements
  • Earth’s Weather Satellites Catch Cloud Changes… On Venus
  • Scientists Find Common Factors In People Who Have “Out-Of-Body” Experiences
  • Shocking Photos Reveal Extent Of Overfishing’s Impact On “Shrinking” Cod
  • Direct Fusion Drive Could Take Us To Sedna During Its Closest Approach In 11,000 Years
  • Earth’s Energy Imbalance Is More Than Double What It Should Be – And We Don’t Know Why
  • We May Have Misjudged A Fundamental Fact About The Cambrian Explosion
  • The Shoebill Is A Bird So Bizarre That Some People Don’t Even Believe It’s Real
  • Colossal’s “Dire Wolves” Are Now 6 Months Old – And They’ve Doubled In Size
  • How To Fake A Fossil: Find Out More In Issue 36 Of CURIOUS – Out Now
  • Is It True Earth Used To Take 420 Days To Orbit The Sun?
  • One Of The Ocean’s “Most Valuable Habitats” Grows The Only Flowers Known To Bloom In Seawater
  • World’s Largest Digital Camera Snaps 2,104 New Asteroids In 10 Hours, Mice With 2 Dads Father Their Own Offspring, And Much More This Week
  • Simplest Explanation For “Anomalous” Signals Coming From Underneath Antarctica Ruled Out
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version